Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALLR NASDAQ:ASRT NASDAQ:EQ NASDAQ:QNCX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALLRAllarity Therapeutics$1.61-8.5%$1.43$0.61▼$2.35$23.38M0.22609,224 shs476,765 shsASRTAssertio$0.84-4.6%$0.83$0.51▼$1.16$80.36M0.28319,996 shs343,475 shsEQEquillium$1.34-6.9%$1.44$0.27▼$2.35$79.73M1.53741,770 shs337,590 shsQNCXQuince Therapeutics$1.87-8.3%$1.65$0.69▼$2.45$100.45M1.07422,463 shs488,527 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALLRAllarity Therapeutics-8.52%+3.87%-11.05%+59.41%+9.52%ASRTAssertio-4.56%-8.19%+3.70%+20.84%-23.39%EQEquillium-6.94%+0.75%-27.17%+282.86%+48.89%QNCXQuince Therapeutics-8.33%+13.33%+16.15%+2.75%+167.14%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALLRAllarity Therapeutics$1.61-8.5%$1.43$0.61▼$2.35$23.38M0.22609,224 shs476,765 shsASRTAssertio$0.84-4.6%$0.83$0.51▼$1.16$80.36M0.28319,996 shs343,475 shsEQEquillium$1.34-6.9%$1.44$0.27▼$2.35$79.73M1.53741,770 shs337,590 shsQNCXQuince Therapeutics$1.87-8.3%$1.65$0.69▼$2.45$100.45M1.07422,463 shs488,527 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALLRAllarity Therapeutics-8.52%+3.87%-11.05%+59.41%+9.52%ASRTAssertio-4.56%-8.19%+3.70%+20.84%-23.39%EQEquillium-6.94%+0.75%-27.17%+282.86%+48.89%QNCXQuince Therapeutics-8.33%+13.33%+16.15%+2.75%+167.14%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALLRAllarity Therapeutics 2.00Hold$9.25474.53% UpsideASRTAssertio 2.00Hold$2.38184.43% UpsideEQEquillium 1.67Reduce$1.00-25.37% DownsideQNCXQuince Therapeutics 3.00Buy$8.14335.45% UpsideCurrent Analyst Ratings BreakdownLatest ALLR, EQ, QNCX, and ASRT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025ALLRAllarity TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025ASRTAssertioWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025EQEquilliumWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025QNCXQuince TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025ALLRAllarity TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025ASRTAssertioWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025EQEquilliumWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025QNCXQuince TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/26/2025ALLRAllarity TherapeuticsAscendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$9.00 ➝ $9.259/26/2025QNCXQuince TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$4.008/26/2025QNCXQuince TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold(Data available from 10/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALLRAllarity TherapeuticsN/AN/AN/AN/A$1.62 per shareN/AASRTAssertio$124.96M0.64$0.05 per share17.01$1.27 per share0.66EQEquillium$41.10M1.94N/AN/A$0.54 per share2.48QNCXQuince TherapeuticsN/AN/AN/AN/A$0.69 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALLRAllarity Therapeutics-$24.51MN/A0.00N/AN/AN/A-173.31%-102.57%11/13/2025 (Estimated)ASRTAssertio-$21.58M-$0.45N/A27.83N/A-36.97%-38.19%-15.45%11/10/2025 (Estimated)EQEquillium-$8.07M-$0.56N/AN/AN/AN/A-139.56%-90.56%11/12/2025 (Estimated)QNCXQuince Therapeutics-$56.83M-$1.09N/AN/AN/AN/A-187.49%-42.47%11/12/2025 (Estimated)Latest ALLR, EQ, QNCX, and ASRT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/15/2025Q2 2025ALLRAllarity Therapeutics-$0.21-$0.15+$0.06-$0.15N/AN/A8/14/2025Q2 2025EQEquillium-$0.14-$0.16-$0.02-$0.16N/AN/A8/11/2025Q2 2025ASRTAssertio-$0.10-$0.17-$0.07-$0.17$27.86 million$29.22 million8/11/2025Q2 2025QNCXQuince Therapeutics-$0.28-$0.34-$0.06-$0.34N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALLRAllarity TherapeuticsN/AN/AN/AN/AN/AASRTAssertioN/AN/AN/AN/AN/AEQEquilliumN/AN/AN/AN/AN/AQNCXQuince TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALLRAllarity TherapeuticsN/A2.312.31ASRTAssertio0.421.591.34EQEquilliumN/A1.651.65QNCXQuince Therapeutics1.455.005.00Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALLRAllarity Therapeutics11.53%ASRTAssertio48.96%EQEquillium27.05%QNCXQuince Therapeutics30.75%Insider OwnershipCompanyInsider OwnershipALLRAllarity Therapeutics0.08%ASRTAssertio4.00%EQEquillium31.60%QNCXQuince Therapeutics20.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALLRAllarity Therapeutics1014.52 million14.51 millionNot OptionableASRTAssertio2096.24 million92.39 millionOptionableEQEquillium4059.50 million40.70 millionNot OptionableQNCXQuince Therapeutics6053.71 million42.81 millionOptionableALLR, EQ, QNCX, and ASRT HeadlinesRecent News About These CompaniesQuince Therapeutics presents data from patient-reported walking capacity at CNSOctober 10 at 8:43 AM | msn.comQuince Therapeutics' (QNCX) Sell (D-) Rating Reaffirmed at Weiss RatingsOctober 10 at 6:03 AM | marketbeat.comQuince Therapeutics Presents Data from Patient-Reported Walking Capacity in Children with Ataxia-Telangiectasia at 54th Child Neurology Society Annual MeetingOctober 9 at 4:05 PM | businesswire.comQuince Therapeutics, Inc. (NASDAQ:QNCX) Given Consensus Recommendation of "Buy" by AnalystsOctober 9 at 3:09 AM | americanbankingnews.comQuince Therapeutics, Inc. (NASDAQ:QNCX) Receives Consensus Recommendation of "Buy" from BrokeragesOctober 4, 2025 | marketbeat.comQuince Therapeutics, Inc. (QNCX) Analyst/Investor Day TranscriptOctober 2, 2025 | seekingalpha.comQuince Therapeutics (NASDAQ:QNCX) Trading Up 1.2% - What's Next?October 1, 2025 | americanbankingnews.comQuince Therapeutics (NASDAQ:QNCX) Stock Price Up 1.2% - Time to Buy?October 1, 2025 | marketbeat.comQuince Therapeutics' (QNCX) "Buy" Rating Reaffirmed at D. Boral CapitalSeptember 26, 2025 | marketbeat.comQuince Therapeutics Announces CPT: Pharmacometrics & Systems Pharmacology Publication of eDSP Population Pharmacokinetic Modeling StudySeptember 25, 2025 | businesswire.comQuince Therapeutics, Inc. - Special CallSeptember 24, 2025 | seekingalpha.comQuince Therapeutics to Host Virtual Investor Day on October 2, 2025September 11, 2025 | businesswire.comQuince Therapeutics, Inc. (NASDAQ:QNCX) Receives Average Rating of "Buy" from BrokeragesSeptember 11, 2025 | marketbeat.comQuince Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 2, 2025 | businesswire.comQuince Therapeutics Inc News (QNCX) - Investing.comAugust 22, 2025 | investing.comQuince Therapeutics price target lowered to $8 from $9 at Citizens JMPAugust 12, 2025 | msn.comQuince Therapeutics Reports Q2 2025 Financial ResultsAugust 12, 2025 | msn.comQuince Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial ResultsAugust 11, 2025 | businesswire.comJMP Securities Initiates Coverage of Quince Therapeutics (QNCX) with Market Outperform RecommendationAugust 5, 2025 | msn.comQuince Therapeutics, Inc. (QNCX) - Yahoo FinanceJuly 17, 2025 | finance.yahoo.comQuince Therapeutics Completes Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-TelangiectasiaJuly 16, 2025 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 2025The Fed Cut Rates: What Now for the S&P 500 and Equity Markets?By Thomas Hughes | September 18, 2025Why Datavault May Be the Penny AI Stock Investors Have Waited ForBy Nathan Reiff | September 22, 2025Costco Investors Will Get a “Special” Treat for ChristmasBy Thomas Hughes | September 29, 20253 REITs to Watch as Rate Cuts Ignite a Real Estate Super CycleBy Gabriel Osorio-Mazilli | October 7, 2025ALLR, EQ, QNCX, and ASRT Company DescriptionsAllarity Therapeutics NASDAQ:ALLR$1.61 -0.15 (-8.52%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$1.61 +0.00 (+0.25%) As of 10/10/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.Assertio NASDAQ:ASRT$0.84 -0.04 (-4.56%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$0.82 -0.01 (-1.20%) As of 10/10/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Assertio Holdings, Inc., a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.Equillium NASDAQ:EQ$1.34 -0.10 (-6.94%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$1.31 -0.03 (-2.24%) As of 10/10/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.Quince Therapeutics NASDAQ:QNCX$1.87 -0.17 (-8.33%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$1.82 -0.06 (-2.94%) As of 10/10/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom Gets Second $420 Target as CPO Win Boosts Outlook AST SpaceMobile's Big Win: Shares Soar on New Deal With Verizon Bassett Furniture: Buy Now, Sit Back, and Collect Dividends Why Amazon’s Prime Day May Be the Catalyst for a Year-End Rally PepsiCo’s Deep Discount Will Soon Evaporate: Buy It While You Can Bargain Alert: DraftKings Is the Most Oversold It’s Ever Been Constellation Brands: Buffett’s $2.2B Bet May Have Hit Bottom How Gamers Are Powering Microsoft’s Next Wave of Growth Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
